Raul Ахнафович Sharipov

Prof. Raul Ахнафович Sharipov

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2026 in Diseases
Verified
Journal Article
Open access
PDF file
Dmitry KudlayDmitry Kudlay
Dmitry Kudlay
ASAdilya Sabirova
Adilya Sabirova
OKOlesya Koroteeva
Olesya Koroteeva
Igor KudryavtsevIgor Kudryavtsev
Igor Kudryavtsev
ARArtem Rubinstein
Artem Rubinstein
DKDmitry Kudlay
Dmitry Kudlay
Background/Objectives: Latent tuberculosis infection (LTBI) represents a critical reservoir for subsequent development of active tuberculosis (ATB) and poses significant challenges for early diagnosis and disease prevention. Traditional immunological assays, such as interferon-gamma release assays (IGRAs), are limited in their ability to reliably distinguish LTBI from ATB. Recent advances in high-throughput omics technologies and machine learning (ML) approaches offer new opportunities for precise, biomarker-based differential diagnostics. Methods: Transcriptomic and proteomic profiling of host immune responses has revealed reproducible gene and protein signatures associated with LTBI and ATB. The integration of ML techniques—including feature selection, dimensionality reduction, multimodal learning, and explainable AI—facilitates the construction of robust diagnostic models. Single-modality signatures, derived from RNA-seq, microarrays, or proteomic assays, are complemented by multimodal approaches that incorporate soluble mediators, immunological readouts, and imaging-derived features. Deep learning frameworks, such as convolutional neural networks and transformer-based architectures, enhance the extraction of complex molecular and structural patterns from high-dimensional datasets. Results: ML-driven analyses of transcriptomic and proteomic data consistently outperform conventional immunological tests in terms of sensitivity, specificity, and clinical applicability. Multimodal integration further improves diagnostic accuracy and robustness. These advances support the translational development of concise, quantitative reverse transcription PCR (qRT-PCR)-based biomarker panels suitable for routine clinical application, enabling early and reliable differentiation between LTBI and ATB. Overall, the combination of high-throughput omics and AI-based analytical frameworks provides a promising pathway for enhancing global tuberculosis diagnostics. Conclusions: This review provides a structured and critical synthesis of transcriptomic and proteomic biomarker research for LTBI and ATB discrimination, with a particular emphasis on machine learning–based analytical frameworks. Unlike previous narrative reviews, we systematically compare data-generating platforms, modelling strategies, validation approaches, and sources of heterogeneity across studies. We further identify key translational barriers, including cohort homogeneity, platform dependency, and limited external validation, and propose directions for future research aimed at improving clinical applicability.

22 December 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
Dmitry KudlayDmitry Kudlay
Dmitry Kudlay
ASAdilya Sabirova
Adilya Sabirova
Igor KudryavtsevIgor Kudryavtsev
Igor Kudryavtsev
ARArtem Rubinstein
Artem Rubinstein
AAArthur Aquino
Arthur Aquino
DKDmitry Kudlay
Dmitry Kudlay
Latent tuberculosis infection (LTBI) represents a biologically active yet clinically asymptomatic stage of Mycobacterium tuberculosis (Mtb) persistence. This condition is characterized by subtle immunometabolic alterations reflecting the host–pathogen equilibrium. Understanding the mechanisms and biomarkers associated with the preclinical phase of LTBI is crucial for preventing progression to active tuberculosis (ATB). Recent advances have identified multiple immunological, transcriptomic, metabolic, and imaging-based approaches that enable stratification of individuals at increased risk of LTBI reactivation. Quantitative assays such as IGRA, multiplex and T-cell activation marker (TAM) tests, as well as interferon-related transcriptional signatures, demonstrate predictive potential when combined with functional assays (MGIA) and metabolic imaging (PET/CT). Experimental primate models faithfully reproduce the spectrum from latency to reactivation, allowing for validation of biomarkers and vaccine or immunomodulatory strategies. The review also highlights the particular challenges of multidrug-resistant LTBI (MDR-LTBI), where standard chemoprophylaxis is less effective and immune control plays a decisive role. The preclinical phase of LTBI constitutes a key point in the TB control cascade. Integrating immunological, transcriptomic, and radiological data into risk-based screening algorithms could substantially improve early detection and targeted prevention. Translating research-derived signatures into clinically applicable, standardized, and cost-effective diagnostic tools requires coordinated international efforts, technological transfer, and policy-level support to reduce TB reactivation and transmission, including MDR-TB.

22 March 2026 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
ASA. R. Sabirova
A. R. Sabirova
RSRaul Ахнафович Sharipov
Raul Ахнафович Sharipov
RTR. K. Tukfatullin
R. K. Tukfatullin
IDI. F. Dovgalyuk
I. F. Dovgalyuk
DKDmitry Kudlay
Dmitry Kudlay
Dmitry KudlayDmitry Kudlay
Dmitry Kudlay
The detection of latent tuberculosis infection (LTBI) is essential for improving the epidemiological situation in the region. As tuberculosis prevalence declines, identifying LTBI in risk groups becomes increasingly significant. At present, no method exists that can reliably confirm or exclude the presence of latent tuberculosis infection. In this study, we analyzed 71 publications on methods for LTBI detection, including modern immunological tests based on Mycobacterium tuberculosis antigens ESAT-6 and CFP-10, as well as interferon-γ release assays (IGRAs). Developing diagnostic strategies for LTBI is particularly relevant for individuals with diabetes mellitus, congenital or acquired immunodeficiency, those receiving immunosuppressive therapy, patients undergoing hemodialysis, as well as for children and the elderly. The search for novel LTBI biomarkers using artificial intelligence, aimed at improving detection and predicting the progression to active tuberculosis seems to be promising advancement in phthisiology.

26 September 2023 in Molecular Genetics Microbiology and Virology (Russian version)
Verified
Journal Article
Closed access
RSRaul Ахнафович Sharipov
Raul Ахнафович Sharipov
MOM.A. Omarov
M.A. Omarov
AMA.R. Mulyukov
A.R. Mulyukov
ADA.I. Dybova
A.I. Dybova
EVE.T. Vyaseleva
E.T. Vyaseleva
EGE.A. Gubaeva
E.A. Gubaeva
The discovery of the CRISPR-Cas9 genetic scissors technology was a breakthrough in the development of gene therapy methods and attracted the attention of the entire scientific community. This technology offers promise for the treatment of many neurodegenerative and oncological diseases that were previously considered almost incurable. Today, the mechanisms of development and progression of these groups of nosologies are becoming more and more studied thanks to discoveries in the field of molecular biology and genetics. However, the application of CRISPR-Cas9 technology has some limitations and difficulties that must be taken into account. The development of gene transporters, a thorough safety assessment of modern genetic manipulation tools, and an integrated approach by experts from different fields of science will all be important to solve the problems associated with the use of CRISPR-Cas9 technology and achieve the desired therapeutic effect.

6 March 2023 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
MYM. M. Yunusbaeva
M. M. Yunusbaeva
LBL. Ya. Borodina
L. Ya. Borodina
AZA. M. Zakirova
A. M. Zakirova
RSRaul Ахнафович Sharipov
Raul Ахнафович Sharipov
BYB. B. Yunusbayev
B. B. Yunusbayev
В обзоре представлены данные из 55 литературных источников, описывающих взаимосвязь микробиома кишечника c туберкулезом. Обсуждаются механизмы, с помощью которых микробиота кишечника может влиять на различные звенья иммунной системы, представлены данные о влиянии противотуберкулезных препаратов на микробиом кишечника, а также возможные перспективы использования пробиотиков в лечении и профилактике туберкулеза.

9 November 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Dmitry KudlayDmitry Kudlay
Dmitry Kudlay
ASAdilia Sabirova
Adilia Sabirova
OKOlesia Koroteeva
Olesia Koroteeva
RSRaul Ахнафович Sharipov
Raul Ахнафович Sharipov
APAleksandr Panteleev
Aleksandr Panteleev
DKDmitry Kudlay
Dmitry Kudlay
Background: Individuals receiving immunosuppressive therapy, solid-organ transplant recipients, household contacts of patients with tuberculosis, and healthcare workers are at increased risk of Mycobacterium tuberculosis infection and progression to tuberculosis disease. However, currently available immunological tests cannot reliably distinguish tuberculosis infection from active tuberculosis disease or predict individual progression to disease. We aimed to assess the prevalence of immunological evidence of tuberculosis infection across clinically and epidemiologically distinct risk groups and to explore the potential of machine-learning methods for individualised risk stratification. Methods: In this observational study, 544 adults aged 18–75 years were assessed between 2023 and 2026. Participants included patients with pulmonary tuberculosis, tuberculosis-facility healthcare workers, healthcare workers in the general medical network, household and occupational contacts of patients with tuberculosis, patients with rheumatic diseases receiving immunosuppressive therapy, patients undergoing assessment for heart transplantation, heart-transplant recipients, and healthy controls. Participants underwent clinical, epidemiological, radiological, and immunological assessment, including interferon-γ release assays (ELISPOT and QuantiFERON-TB Gold) and the tuberculosis recombinant allergen skin test. Individuals with positive immunological tests underwent additional assessment to exclude active tuberculosis. Exploratory logistic regression and decision-tree models were developed separately for each risk group using demographic and treatment-related variables. Model performance was estimated using repeated stratified 5-fold cross-validation (5 × 10 repeats) with bootstrap optimism correction; discrimination, calibration, sensitivity, specificity, positive and negative predictive values, Cohen’s kappa, and Matthews correlation coefficient were reported with 95% confidence intervals. Results: The prevalence of positive immunological tests was highest among heart-transplant recipients (15 [53.6%] of 28), followed by household contacts (12 [41.4%] of 29), patients undergoing pre-transplant assessment (5 [35.7%] of 14), and tuberculosis-facility healthcare workers (21 [22.6%] of 93). Positivity was lower among patients with rheumatic diseases receiving immunosuppressive therapy (11 [13.9%] of 79) and healthcare workers in the general medical network without documented tuberculosis exposure (7 [10.5%] of 68), and was 3 (4.4%) of 69 among healthy controls. Compared with healthy controls, positivity was significantly higher among tuberculosis-facility healthcare workers, household contacts, patients with rheumatic diseases, and pre-transplant and heart-transplant populations. Exploratory machine-learning analyses were performed separately for the two clinically most relevant immunosuppressed subgroups. In patients with rheumatic diseases (n = 71; 9 positive, 62 negative), pooled ROC AUC was 0.670 (95% CI 0.520–0.824, participant-level bootstrap); age showed 100% bootstrap sign consistency, whereas bDMARD treatment showed 84.6% and sex 55.0%. In the combined heart transplantation group (n = 41; 19 positive, 22 negative), pooled ROC AUC was 0.668 (95% CI 0.522–0.811); tacrolimus and everolimus showed the highest bootstrap sign consistency (100% and 97.6%, respectively); however, because tacrolimus and everolimus are administered predominantly to transplant recipients, these coefficients may partly reflect transplantation status rather than drug-specific effects. Because the heart transplantation group combines pre-transplant candidates and recipients, and because both subgroups had small numbers of events, these associations should be interpreted as exploratory and not as drug-specific causal effects. Conclusions: The prevalence of immunological evidence of tuberculosis infection varied substantially between risk groups and was particularly high among household contacts and heart-transplant recipients. The findings suggest that epidemiological exposure and the type of immunosuppressive therapy should be considered jointly when assessing tuberculosis infection risk. Exploratory machine-learning analyses suggested that treatment-related variables may contribute to individualised risk stratification in the combined heart transplantation group, but the models were developed in small, clinically heterogeneous subgroups and were not externally validated. They should therefore be regarded as hypothesis-generating. Prospective multicentre studies with longitudinal follow-up are required to determine whether integrated clinical, epidemiological, immunological, and treatment-related models can predict incident tuberculosis disease and improve targeted preventive strategies.